Who is affected by this change?

This affects Independence Blue Cross Oncology, Neurology, Pediatrics providers on Commercial plans.

When does this change take effect?

This change is effective Dec 19, 2025.

Back to dashboard

CommercialCoverageLow impact

08.02.37, Eladocagene exuparvovec-tneq (Kebilidi™)

Independence Blue Cross·Oncology, Neurology, Pediatrics·Pharmacy

Effective date

Dec 19, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

IBX has updated their commercial policy for Eladocagene exuparvovec-tneq (Kebilidi™), a gene therapy drug. The reissued policy will be effective December 19, 2025, with updated coverage or administration requirements for this specialty pharmaceutical product.

Action Required

Action needed

By December 19, 2025: Review the full policy details at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Eladocagene exuparvovec-tneq (Kebilidi™). Update billing workflows if this gene therapy is prescribed in your practice.

Related policy hubs

Independence Blue Cross policies Oncology Neurology Pediatrics